Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39th Annual Strategic Decisions Conference on May 31st at the New York Hilton Midtown. Joaquin Duato, Chairman of the Board and CEO, will represent the company in a session scheduled for 10:00 a.m. (Eastern Time).
This event will be accessible to investors and interested parties via the Johnson & Johnson website at www.investor.jnj.com. A replay of the webcast will be available approximately 48 hours after the live session.
Johnson & Johnson (NYSE: JNJ) has announced the launch of a roadshow for the initial public offering (IPO) of its subsidiary, Kenvue Inc., offering 151,204,000 shares at an expected price of $20.00 to $23.00 per share. The underwriters will have a 30-day option to purchase an extra 22,680,600 shares. After the IPO, JNJ will hold 91.9% of Kenvue's shares. Goldman Sachs, J.P. Morgan, and BofA Securities are leading the IPO, with a registration statement filed with the SEC that is not yet effective. The press release emphasizes the commitment of JNJ to health and wellness, along with a cautionary note on forward-looking statements regarding the IPO and economic factors impacting Kenvue's success as a standalone company.
Lawyers for around 55,000 plaintiffs in the lawsuit against Johnson & Johnson (JNJ) over cancer-linked talcum powder have formed an Ad Hoc Committee. They support an $8.9 billion settlement aimed at resolving a lengthy legal battle. LTL Management, a J&J subsidiary, is again filing for Chapter 11 bankruptcy to create a trust for compensating affected victims.
The proposed settlement includes removing all talc-based products globally and ensuring compensation for current claimants within a year. The Ad Hoc Committee, which has retained bankruptcy counsel, needs a 75% claimant approval for the settlement to pass. This follows scientific evidence linking J&J's products to serious health issues, as well as previous bankruptcy attempts that were rejected by the courts.
Johnson & Johnson (JNJ) reported a 5.6% increase in first-quarter 2023 sales, reaching $24.7 billion. The operational growth was 9.0%*, with adjusted operational growth at 7.6%*. The basic loss per share was ($0.03), showing a 101.6% decrease due to a one-time charge, while adjusted earnings per share (EPS) rose 0.4%* to $2.68. The company is increasing its 2023 full-year guidance for adjusted operational sales and EPS. Key segment performances included Consumer Health, up 11.3%*, Pharmaceuticals, up 7.2%*, and MedTech, with a 6.4%* increase. Positive developments included CHMP opinion for AKEEGA and promising results for CARVYKTI and Nipocalimab studies.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
